AelisFarma

A powerful, diverse and growing pipeline

AelisFarma

AEF0117 for cannabis related disorders

 
AEF0117 has obtained an FDA IND in 2016 and is currently in phase II in the United States.
 
AEF0117 is a new molecular entity (NME) developed by Aelis Farma for the treatment of Cannabis addiction and Cannabis induced Psychosis.
 
AEF0117 major characteristics:
 
Very high potency in inhibiting the effects of cannabis active principle THC in several animal species including non-human primates without side effects on normal behavior.
Very favorable ADMET profile, with good oral absorption, brain access, long half-life and no toxic or adverse effects identified (Therapeutic index >14 000)
Excellent safety profile and PK characteristics in humans.

 

 

AEF0217 for cognitive disorders

 
AEF0217 will enter clinical phase I trials in 2020 in Europe.
 
AEF0217 is a second NME developed by Aelis Farma for the treatment of the cognitive deficit of Down syndrome and the subjective cognitive impairment of the elderly.
 
AEF0217 major characteristics:
 
Very high potency in reversing cognitive deficits in animal models of Down syndrome and aging.
No behavioral side effects even in the fragile trisomic and aging mice.
Very favorable ADMET profile, with good oral absorption, brain access, long half-life and no toxic or adverse effect identified to date.

 

 

New CB1-SSi for other cannabinoids-dependent diseases

 
Aelis Farma’s screening platform provides a steady flow of new drug candidates.
 
New CB1-SSi are NME with an original and proprietary structure providing follow up for AEF0117 and AEF0217 and drug candidates for the treatment of other cannabinoids-dependent diseases.
 
New CB1-SSi potential disease targets:
 
Myopathies: Duchene Myopathy
Metabolic disorders: diabetes and atherosclerosis
Fibrotic diseases: liver (NASH), lung, kidney and skin fibrosis

 

 

 

A powerful, diverse and growing pipeline

AelisFarma